Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues

Journal of Medical Primatology

Volumn 42, Issue 2, 2013, Pages 89-100

  Tsuiki, Ai ^a   Luo, Wei ^b   Henning, Tara ^b   Vishwanathan, Sundaram ^b   Dinh, Chuong ^c   Adams, Debra ^b   Sweeney, Elizabeth ^b   Mitchell, James ^b   Bachman, Shannon ^b   Sharma, Prachi ^d   Powell, Nathaniel ^a   Hendry, Michael ^b   Mcnicholl, Janet ^b   Kersh, Ellen ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c TOTAL   (France)

^d EMORY UNIVERSITY   (United States)

Author keywords

Genital; HIV; Non human primates; Topical gel

Indexed keywords

FINGOLIMOD; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 8; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; INFLAMMATORY CELL; MACACA NEMESTRINA; MICROENVIRONMENT; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CONTENT; TISSUE LEVEL; UTERINE CERVIX; VAGINA FLORA; VAGINA MUCOSA; VAGINAL SECRETION;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTI-INFECTIVE AGENTS; CERVIX UTERI; DRUG EVALUATION, PRECLINICAL; FEMALE; HIV INFECTIONS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-8; LYMPHOCYTE COUNT; MACACA NEMESTRINA; MUCOUS MEMBRANE; PILOT PROJECTS; PLACEBOS; PROPYLENE GLYCOLS; SPHINGOSINE; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

MACACA NEMESTRINA; PRIMATES;

EID: 84874940610     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/jmp.12033     Document Type: Article

References (43)

1. Abdool Karim SS, Baxter C: Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol, 2012; 26:427-39.
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, Caprisa Trial Group: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010; 329:1168-74.
3. Begaud E, Chartier L, Marechal V, Ipero J, Leal J, Versmisse P, Breton G, Fontanet A, Capoulade-Metay C, Fleury H, Barre-Sinoussi F, Scott-Algara D, Pancino G: Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology, 2006; 3:35.
4. Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem, 2003; 278:47408-15.
5. Brinkmann V, Pinschewer D, Chiba K, Feng L: FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci, 2000; 21:49-52.
6. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S, Burtin P: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov, 2010; 9:883-97.
7. CDC. HIV Surveillance Report - Diagnoses of HIV infection and AIDS in the United States and Dependent Areas, Vol22. 2010 [cited 2012 July]; Available from: http://www.cdc.gov/hiv/surveillance/resources/reports/2010report/pdf/2010_HIV_Surveillance_Report_vol_22.pdf#Page=1.
8. Chiba K: FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther, 2005; 108:308-19.
9. Council NR: Guide for the Care and Use of Laboratory Animals, Eighth Edition, Washington, D.C.: National Academy Press, 2011.
10. Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Haring DA, Francis G, Kappos L, Freedoms Study Group: Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol, 2012; 11:420-8.
11. Gasperini C, Ruggieri S: Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. Drug Des Devel Ther, 2012; 6:175-86.
12. Gomez CA: Preventing HIV in U.S. women and girls: a call for social action. Women's Health Issues 2011; 21(6 Suppl):S287-94.
13. Graler MH, Goetzl EJ: The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J, 2004; 18:551-3.
14. Hira SK, Feldblum PJ, Kamanga J, Mukelabai G, Weir SS, Thomas JC: Condom and nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples in Zambia. Int J STD AIDS, 1997; 8:243-50.
15. Jennes W, Evertse D, Borget MY, Vuylsteke B, Maurice C, Nkengasong JN, Kestens L: Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin Exp Immunol, 2006; 143:435-44.
16. Kamali A, Byomire H, Muwonge C, Bakobaki J, Rutterford C, Okong P, Profy A, Byaruhanga R, Namukwaya S, McCormack S, Grosskurth H, Nunn AJ, Lacey CJ: A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect, 2010; 86:222-6.
17. Kersh EN, Luo W, Adams DR, Mitchell J, Garcia-Lerma JG, Butera S, Folks T, Otten R: Evaluation of the lymphocyte trafficking drug FTY720 in SHIVSF162P3-infected rhesus macaques. J Antimicrob Chemother, 2009; 63:758-62.
18. Kitabayashi H, Isobe M, Watanabe N, Suzuki J, Yazaki Y, Sekiguchi M: FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol, 2000; 35:410-6.
19. Kovarik JM, Hartmann S, Bartlett M, Riviere GJ, Neddermann D, Wang Y, Port A, Schmouder RL: Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm Drug Dispos, 2007; 28:97-104.
20. Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, Fichorova RN, Crucitti T, Vanham G, Arien KK: Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS ONE, 2012; 7:e43951.
21. Lan YY, De Creus A, Colvin BL, Abe M, Brinkmann V, Coates PT, Thomson AW: The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am J Transplant, 2005; 5:2649-59.
22. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT: Glycerol monolaurate prevents mucosal SIV transmission. Nature, 2009; 458:1034-8.
23. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L, HPTN 050 Protocol Team: Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS, 2006; 20:543-51.
24. McCormack S, Hayes R, Lacey CJ, Johnson AM: Microbicides in HIV prevention. BMJ, 2001; 322:410-3.
25. McLaren PJ, Ball TB, Wachihi C, Jaoko W, Kelvin DJ, Danesh A, Kimani J, Plummer FA, Fowke KR: HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J Infect Dis, 2010; 202(Suppl 3):S339-44.
26. Miller CJ, Shattock RJ: Target cells in vaginal HIV transmission. Microbes Infect, 2003; 5:59-67.
27. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase AT: Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol, 2005; 79:9217-27.
28. Murooka TT, Deruaz M, Marangoni F, Vrbanac VD, Seung E, von Andrian UH, Tager AM, Luster AD, Mempel TR: HIV-infected T cells are migratory vehicles for viral dissemination. Nature, 2012; 490:283-7.
29. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH, Caprisa Traps Team: Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis, 2012; 206:993-1001.
30. Ngugi EN, Plummer FA, Simonsen JN, Cameron DW, Bosire M, Waiyaki P, Ronald AR, Ndinya-Achola JO: Prevention of transmission of human immunodeficiency virus in Africa: effectiveness of condom promotion and health education among prostitutes. Lancet, 1988; 2:887-90
31. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S: Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol, 2002; 29:707-16.
32. Parikh UM, Dobard C, Sharma S, Cong ME, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W: Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol, 2009; 83:10358-65.
33. Pleass R, Camp R: Cytokines induce lymphocyte migration in vitro by direct, receptor-specific mechanisms. Eur J Immunol, 1994; 24:273-6.
34. Pope M, Haase AT: Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med, 2003; 9:847-52.
35. Quesniaux V, Fullard L, Arendse H, Davison G, Markgraaff N, Auer R, Ehrhart F, Kraus G, Schuurman HJ: A novel immunosuppressant, FTY720, induces peripheral lymphodepletion of both T- and B cells and immunosuppression in baboons. Transpl Immunol, 1999; 7:149-57.
36. Reines I, Kietzmann M, Mischke R, Tschernig T, Luth A, Kleuser B, Baumer W: Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration. J Invest Dermatol, 2009; 129:1954-62.
37. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, Cost M, Huang Y, Gai F, Billitto N, Lynam JD, Pryke K, Graebing P, Hopkins N, Rooney JF, Friend D, Dezzutti CS: In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS ONE, 2010; 5:e9310.
38. Turmen T: Gender and HIV/AIDS. Int J Gynaecol Obstet 2003; 82:411-8.
39. UNAIDS. Global Report - UNAIDS Report on the Global AIDS Epidemic. 2010 [cited 2012 April]; Available from: http://www.unaids.org/globalreport/Global_report.htm.
40. Weller S, Davis K: Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev, 2002; CD003255.
41. WHO. HIV/AIDS - Fact sheet N°360. 2012 [cited 2012; Available from: http://www.who.int/mediacentre/factsheets/fs360/en/index.html.
42. Zeng X, Wang T, Zhu C, Xing X, Ye Y, Lai X, Song B, Zeng Y: Topographical and biological evidence revealed FTY720-mediated anergy-polarization of mouse bone marrow-derived dendritic cells in vitro. PLoS ONE, 2012; 7:e34830.
43. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA, Rogan M, Cavert W, Miller CJ, Veazey RS, Notermans D, Little S, Danner SA, Richman DD, Havlir D, Wong J, Jordan HL, Schacker TW, Racz P, Tenner-Racz K, Letvin NL, Wolinsky S, Haase AT: Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science, 1999; 286:1353-7.